ExpreS2ion Biotechnologies – Rights Issue
Subject to a subsequent approval at an extraordinary general meeting in the Company on 23 March 2023, ExpreS2ion will carry through a rights issue of units consisting of shares and warrants of series with preferential rights for existing shareholders. If fully subscribed, a rights issue that will raise about SEK 102m in cash before cost in the first round. Around 50% of the right issue is covered.
In the event, we will focus on the details of the rights issue and attached warrant program, the use of the proceeds, and the options you have as an investor with preferential rights. There will be a live Q&A at the end.
Read more details about the offering at https://investor.expres2ionbio.com/press-releases-cision/ or https://www.inderes.dk/analyst-comments/expres2ion-biotechnologies-details-of-the-announced-rights-issue.
ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system. Currently, the company has a late stage pipeline of vaccines against Covid-19, and an early stage pipeline for breast cancer, Influenza, and Malaria.
HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 1:31 PM 13-03-2023.